Rapport Therapeutics (NASDAQ:RAPP) Sets New 52-Week Low – Here’s What Happened

Rapport Therapeutics (NASDAQ:RAPP)’s stock price hit a new 52-week low during trading on Wednesday . The company traded as low as $16.51 and last traded at $16.67, with a volume of 22375 shares changing hands. The stock had previously closed at $17.79.

Rapport Therapeutics Stock Down 6.2 %

The business has a 50-day moving average price of $21.21.

Institutional Investors Weigh In On Rapport Therapeutics

Several institutional investors have recently made changes to their positions in RAPP. Values First Advisors Inc. bought a new stake in Rapport Therapeutics in the third quarter worth about $31,000. BNP Paribas Financial Markets purchased a new stake in Rapport Therapeutics in the third quarter worth $34,000. JPMorgan Chase & Co. bought a new stake in shares of Rapport Therapeutics during the third quarter worth $83,000. SG Americas Securities LLC purchased a new stake in shares of Rapport Therapeutics during the third quarter valued at $101,000. Finally, Sandia Investment Management LP bought a new position in shares of Rapport Therapeutics in the second quarter worth about $116,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.